Abnormal tumor markers (R97) ICD-10-CM
The R97 code range covers abnormal tumor markers with 7 ICD-10-CM diagnosis codes. 5 of them are billable and valid for claim submission in fiscal year 2027, and the category headers group them but cannot themselves be billed.
Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
- Elevated tumor associated antigens [TAA]
- Elevated tumor specific antigens [TSA]
Codes in the R97 Range 7 codes · 5 billable
- R97 Abnormal tumor markersNon-billable
- R97.0 Elevated carcinoembryonic antigen [CEA]
- R97.1 Elevated cancer antigen 125 [CA 125]
- R97.2 Elevated prostate specific antigen [PSA]Non-billable
- R97.20 Elevated prostate specific antigen [PSA]
- R97.21 Rising PSA following treatment for malignant neoplasm of prostate
- R97.8 Other abnormal tumor markers
About the R97 Code Range
These codes describe abnormal tumor marker results, including results above the reference range.
R97 separates elevated carcinoembryonic antigen (CEA) in R97.0, cancer antigen 125 (CA 125) in R97.1, and prostate specific antigen (PSA) in R97.2. R97.8 describes other abnormal tumor markers.
Questions About This Page
How many billable codes are in the R97 range?
Of the 7 codes in this range, 5 are billable and valid for claim submission from October 1, 2026 through September 30, 2027. Category header codes group them but cannot be reported on claims.
What does the R97 range classify?
The range classifies abnormal tumor markers. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2027 ICD-10-CM Tabular List and order file, effective October 1, 2026 through September 30, 2027.
